A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria

• •Have Crohn's disease (CD) or fistulizing Crohn's disease of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
• •Have moderate to severe CD as assessed by CDAI, stool frequency (SF), and abdominal pain (AP) scores, and Simple Endoscopic Score for Crohn's Disease (SES-CD)
• •Have screening laboratory test results within the protocol specified parameters
• •A female participant of childbearing potential must have a negative urine pregnancy test result at screening and baseline
• •Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD